Senior Research Associate II, Cell Isolation/Genome Engineering (23066-R-675-ATA)

Senior FP&A Manager (23041-B-840-FINA)

Gene Editing Intern (23064-T-670-SBIO)

Scientist I - Synthetic Biology (23029-B-670-SBIO)

Equipment Technician (23026-B-850-FAC)

Vice President, Facilities and Engineering (23061-R-850-FAC)

Manufacturing Process Specialist (23020-B-683-MFG)

Senior Manager, High Throughput Assay Development (23035-B-692-AUTO)

Associate Director, Strategic Sourcing (23023-B-685-SC)

Senior Manufacturing Engineer – Manufacturing Technical Services (23022-B-683-MFG)

Scientist, Next Generation Sequencing (23034-B-690-NGS)

Clinical Trial Logistics Associate (23007-B-615-MED)

Research Associate - Flow Cytometry (23027-B-670-IM)

Head of Intellectual Property (23055-R-815-LG)

Quality Control Analyst  II (23018-B-682-QA)

Principal Scientist, Analytical Development (Cell-based Assays) (23052-R-680-PS)

Senior Research Associate, Analytical Development (Flow Cytometry) (23013-B-680-PS)

Senior Research Associate III, Process Development (23009-B-680-PS)

Scientist, Process Development (23008-B-680-PS)

EHS (Environment, Health & Safety) Technician (23025-B-850-FAC)

Senior Process Engineer I (23011-B-680-PS)

Associate Director, Target Biology (23031-B-670-DISC)

Sr. Clinical Trial Manager (22120-R-615-MED)

Manager, ERP (22108-U-830-IS)

Research Associate, Target Validation and Binder Discovery (22084-R-670-DISC)

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Aruvant

Ascidian Therapeutics

Ascribe Bioscience

ArsenalBio is developing programmable immune cell therapies to defeat cancer. CAR T-cell therapies are a recent revelation in developing targeted immune therapies for cancer. However, they have high risk and are high cost for development. Using multi-omics, gene editing technology and synthetic biology, ArsenalBio’s cell therapeutics are optimized for expansion, memory and persistence in vivo to reduce the number of cell infusions and minimize off-target effects. ArsenalBio is therefore enhancing the safety, efficacy and availability of these cell therapies for cancer patients. ArsenalBio has a multi program discovery collaboration with Bristol Myers Squibb to advance T cell therapies for solid tumors.

<p>ArsenalBio is developing programmable immune cell therapies to defeat cancer. CAR T-cell therapies are a recent revelation in developing targeted immune therapies for cancer. However, they have high risk and are high cost for development. Using multi-omics, gene editing technology and synthetic biology, ArsenalBio’s cell therapeutics are optimized for expansion, memory and persistence in vivo to reduce the number of cell infusions and minimize off-target effects. ArsenalBio is therefore enhancing the safety, efficacy and availability of these cell therapies for cancer patients. ArsenalBio has a multi program discovery collaboration with Bristol Myers Squibb to advance T cell therapies for solid tumors.</p>


Find a biotech startup job.